Perimenopause & Menopause.

Summary

Clinical trials of neurokinin B (NKB) signaling antagonists (NK3 receptor antagonists) demonstrate efficacy in reducing vasomotor symptoms in postmenopausal women. The NKB pathway, through its connection to KNDy neurons and the median preoptic nucleus, plays a central role in thermoregulatory dysfunction following estrogen withdrawal. These agents represent a novel non-hormonal approach for VMS management, particularly relevant for women with contraindications to MHT such as hormone-sensitive breast cancer survivors.

Summary

In postmenopausal women, estrogen deficiency leads to changes in urogenital epithelium and the urobiome, predisposing to recurrent urinary tract infections (rUTI). Vaginal estrogen therapy is recognized as a key prevention strategy for rUTI in postmenopausal women by restoring the urogenital epithelium and microbiome. This represents a repurposing context in that vaginal estrogen, while used for genitourinary syndrome of menopause, has a specific evidence-based role in UTI prevention — a distinct clinical endpoint.

Summary

Systematic reviews demonstrate that oral micronized progesterone at 200 mg/day for 12-14 days/month provides effective endometrial protection in postmenopausal women using estrogen therapy for up to 5 years. Importantly, unlike synthetic progestins, estrogen combined with micronized progesterone does not increase breast cancer risk for up to 5 years of use, with only limited evidence of increased risk beyond 5 years. This favorable safety profile positions micronized progesterone as a preferred progestogen component of menopausal hormone therapy.

Summary

Out of 36,976 condition-relevant adverse event reports for escitalopram in the FDA AEMS database (from 85,593 total female-patient reports), vasomotor and mood signals relevant to menopause were prominent including flushing (n=8), hot flush (n=3), night sweats (n=2), cold sweat (n=1), depression (n=12), insomnia (n=7), anxiety (n=9), and fatigue (n=16). Notably, 'night sweats' was listed as a reported indication for escitalopram, confirming clinical use in menopausal symptom management. The strong vasomotor signal relative to other SSRIs in this analysis supports escitalopram's known thermoregulatory efficacy. Full-scale analysis of all reports may reveal additional patterns.

Summary

Multiple international guidelines and meta-analyses support transdermal testosterone therapy for postmenopausal women with hypoactive sexual desire disorder (HSDD). A global consensus position statement endorsed by 11 major societies recommends testosterone for postmenopausal HSDD. Clinical practice guidelines detail identification, dosing (physiologic female range), and monitoring. Evidence also suggests benefits for cognitive performance, musculoskeletal health, and genitourinary syndrome of menopause (GSM). Safety data show no serious adverse events at physiologic doses, though long-term safety data are limited. No approved female formulation exists in most countries, necessitating off-label use of male formulations.

Summary

Estetrol is a native fetal estrogen now commercially available in contraception and undergoing late-stage clinical development for menopausal hormone replacement therapy. Studies demonstrate that E4 selectively activates nuclear estrogen receptor alpha without activating membrane ERα, resulting in tissue-specific estrogenic effects. Clinical data show a lower impact on hemostatic and metabolic parameters compared to other estrogens, potentially reducing thromboembolic risk and dyslipidemia — key concerns with conventional MHT. Its favorable pharmacokinetic profile with minimal CYP450 interactions further supports its potential as a safer HRT option.

Summary

In postmenopausal women, hormone replacement therapy with estrogen counteracts the weight gain and accumulation of abdominal (visceral) fat associated with the menopausal transition. This positions estrogen therapy as having a measurable metabolic benefit beyond its established role in vasomotor symptom relief, with implications for cardiovascular risk reduction. The effect is mediated through estrogen's known inhibitory action on food intake and its role in regulating fat distribution.

Summary

In NCT00704912, clomiphene citrate (a comparator arm in PCOS infertility treatment) was associated with substantial AEs including hot flushes (n=15 total across arms), mood swings (n=19 total), dysmenorrhea (n=20 total), pelvic pain (n=42 total), vaginal dryness/pain (n=4), insomnia (n=5), and abnormal uterine bleeding (n=11). The hot flushes and vaginal dryness pattern mirrors menopausal vasomotor and urogenital symptoms, consistent with clomiphene's anti-estrogenic effects at the hypothalamic and peripheral tissue level.

Summary

In NCT00611923, flutamide treatment in PMDD/PMS patients produced hot flushes (n=2), a vasomotor symptom characteristic of estrogen withdrawal or hormonal disruption relevant to menopause. Anti-androgen therapy can alter the hypothalamic thermoregulatory set point through indirect effects on estrogen-androgen balance, mimicking vasomotor instability seen in menopause. This AE suggests flutamide engages thermoregulatory pathways relevant to menopausal vasomotor symptoms.

Summary

In NCT03749109, hot flush was reported in 2 subjects receiving quinagolide vaginal ring. Hot flushes are a hallmark vasomotor symptom of menopause and may indicate that quinagolide's dopamine agonist activity is modulating hypothalamic thermoregulatory centers or altering estrogen signaling sufficiently to produce menopausal-type vasomotor effects.

Summary

Milnacipran is an SNRI approved for fibromyalgia that inhibits both the serotonin transporter (SLC6A4, Open Targets menopause score 0.481, clinical evidence 0.79) and norepinephrine transporter (SLC6A2, score 0.323, clinical evidence 0.53). Unlike desvenlafaxine, milnacipran has relatively balanced SERT/NET inhibition with greater noradrenergic potency, which may differentially affect thermoregulatory noradrenergic tone. It has not been studied for menopausal vasomotor symptoms.

Summary

Tachykinin receptor 1 (TACR1/NK1R) has a strong association with menopause in Open Targets (overall score 0.482, clinical evidence 0.79). Tachykinin receptor 3 (TACR3/NK3R) is the second highest-scoring target (0.598, genetic association 0.51), and both receptors share the neurokinin signaling pathway. Aprepitant, an NK1R antagonist approved for CINV, could modulate vasomotor symptoms through tachykinin pathway blockade, complementing the NK3R antagonist approach (fezolinetant) recently approved for hot flashes.

Summary

Acyl-CoA synthetase long chain family member 1 (ACSL1) has a genetic association with menopause in Open Targets (overall 0.320, genetic evidence 0.53). ACSL1 is a key enzyme in long-chain fatty acid metabolism and mitochondrial beta-oxidation, processes critically regulated by thyroid hormone. Post-menopausal metabolic shift involves impaired lipid oxidation and increased visceral adiposity, processes where ACSL1 and thyroid signaling intersect.

Summary

Desvenlafaxine targets the serotonin transporter (SLC6A4, Open Targets overall score 0.481, clinical evidence 0.79) and norepinephrine transporter (SLC6A2, score 0.323, clinical evidence 0.53), both of which are independently associated with menopause. This dual monoaminergic action directly addresses the serotonergic and noradrenergic dysregulation that contributes to vasomotor instability following estrogen decline. While desvenlafaxine has Phase 3 data for vasomotor symptoms, its primary approval remains for depression, making this a pathway-validated repurposing case.

Summary

Trimebutine acts as an agonist at multiple opioid receptors but also has documented NK1 receptor antagonist activity. Given that tachykinin receptor 1 (NK1R) has an Open Targets association score of 0.482 with menopause (clinical evidence 0.79), trimebutine's NK1R antagonism could have relevance for vasomotor symptom management. This represents a non-obvious repurposing candidate from the GI drug space.

Summary

MCM8 (minichromosome maintenance 8 homologous recombination repair factor) has a high genetic association score with menopause (overall 0.435, genetic evidence 0.71), reflecting its role in DNA double-strand break repair in oocytes. HELB (DNA helicase B, overall 0.400, genetic 0.66) is similarly involved in DNA repair and oocyte maintenance. Olaparib inhibits PARP-mediated DNA repair, and BRCA/DNA repair deficient women experience earlier menopause — this genetic overlap suggests a shared DNA repair–ovarian reserve axis.

Summary

Tradipitant is a highly selective NK1R antagonist in late-stage development for gastroparesis and pruritus. Tachykinin receptor 1 (TACR1) has a strong Open Targets association with menopause (overall 0.482, clinical evidence 0.79), and the closely related NK3R pathway (TACR3, score 0.598) has already been validated by fezolinetant's approval for vasomotor symptoms. Tradipitant's potent and selective NK1R blockade represents a distinct pharmacological approach within the same tachykinin axis.

Summary

The androgen receptor (AR) is associated with menopause in Open Targets (overall score 0.324, clinical evidence 0.53). Post-menopausal women experience a relative androgen excess due to continued adrenal androgen production alongside estrogen depletion, contributing to symptoms like hirsutism, acne, androgenic alopecia, and potentially metabolic changes. Enzalutamide, a potent AR antagonist, could theoretically address androgen-mediated post-menopausal symptoms.

Summary

Melatonin receptors (MTNR1A and MTNR1B) are targets already being explored in menopause (melatonin is in Phase 2 trials), but tasimelteon — a selective dual MT1/MT2 agonist approved for circadian rhythm disorders — has not been investigated for menopausal symptoms. Post-menopausal women experience significant circadian disruption, insomnia, and reduced melatonin secretion. Tasimelteon's higher receptor selectivity and longer duration of action may offer advantages over exogenous melatonin.

Summary

Fosnetupitant is a prodrug of netupitant, a highly selective NK1R antagonist. TACR1 (NK1R) shows a robust Open Targets association with menopause (overall 0.482, clinical evidence 0.79). Unlike aprepitant, fosnetupitant has an extended half-life and sustained receptor occupancy, which could be advantageous for chronic vasomotor symptom management. The clinical evidence base for the tachykinin pathway in menopause is particularly strong given fezolinetant's validation of the NK3R arm.

Summary

Out of 48,546 condition-relevant adverse event reports for atorvastatin in the FDA AEMS database (from 123,129 total female-patient reports), mood and neurological symptoms including fatigue (n=13), asthenia (n=11), memory impairment (n=5), anxiety (n=3), insomnia (n=2), and depressed level of consciousness (n=1) alongside vasomotor signals (flushing n=2, hyperhidrosis n=1) form a symptom cluster consistent with menopausal complaints. The general population sample's heavy metabolic burden (type 2 diabetes n=75) reflects the post-menopausal cardiovascular risk context. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 5,981 condition-relevant adverse event reports for lovastatin in the FDA AEMS database (from 13,990 total female-patient reports), a notably high concentration of mood/neurological symptoms was observed: fatigue (n=16), memory impairment (n=9), asthenia (n=8), insomnia (n=5), sleep disorder (n=5), confusional state (n=4), cognitive disorder (n=3), anxiety (n=3), depression (n=3), irritability (n=1), depressed mood (n=1). Vasomotor signals include hyperhidrosis (n=2), night sweats (n=1), hot flush (n=1), flushing (n=1). This pattern is consistent with menopausal symptom exacerbation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 46,392 condition-relevant adverse event reports for rosuvastatin in the FDA AEMS database (from 107,207 total female-patient reports), the mood/neurological profile is notably robust: depression (n=7), anxiety (n=6), memory impairment (n=6), insomnia (n=4), fatigue (n=15), irritability (n=1), cognitive disorder (n=2), crying (n=1), and suicidal ideation (n=1), alongside vasomotor symptoms (hyperhidrosis n=4, flushing n=4). The general sample confirms type 2 diabetes mellitus (n=27) as the leading condition, reflecting the metabolic population in which menopause management is clinically important. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 50,392 condition-relevant adverse event reports for simvastatin in the FDA AEMS database (from 126,236 total female-patient reports), prominent vasomotor and mood/neurological signals (hot flush n=3, flushing n=3, night sweats n=1, depression n=5, insomnia n=10, fatigue n=23, asthenia n=16, memory impairment n=1) closely mirror menopausal symptom profiles. These findings are corroborated by the general sample showing type 2 diabetes mellitus as the dominant indication (n=19), reflecting the metabolic context in which menopausal women commonly use statins. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 3,742 condition-relevant adverse event reports for pravastatin in the FDA AEMS database (from 10,007 total female-patient reports), the mood/neurological signal is particularly prominent relative to sample size: anxiety (n=8), fatigue (n=8), insomnia (n=7), asthenia (n=6), depression (n=4), memory impairment (n=3), irritability (n=3), confusional state (n=2), major depression (n=1), and crying (n=1), alongside vasomotor reports (flushing n=3, hot flush n=1, night sweats n=1). This concentration of mood and vasomotor symptoms aligns strongly with menopausal presentation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 1,296 condition-relevant adverse event reports for fluvastatin in the FDA AEMS database (from 3,509 total female-patient reports), the mood/neurological signal is strikingly concentrated: depression (n=11), sleep disorder (n=10), memory impairment (n=9), fatigue (n=17), asthenia (n=8), insomnia (n=5), cognitive disorder (n=1), irritable bowel syndrome (n=1), anxiety (n=1), alongside vasomotor signals (hyperhidrosis n=3, hot flush n=1). These represent the highest proportional mood/cognitive signal among all statins in this analysis, implicating menopausal symptom exacerbation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 19,586 condition-relevant adverse event reports for semaglutide in the FDA AEMS database (from 47,253 total female-patient reports), vasomotor and mood signals relevant to menopause were identified including hot flush (n=1), hyperhidrosis (n=2), depression (n=3), depressed mood (n=2), anxiety (n=8), insomnia (n=4), middle insomnia (n=3), and cognitive symptoms including memory impairment (n=5) and brain fog (n=1), alongside metabolic perturbations. The combination of vasomotor, cognitive, and mood disturbances mirrors the menopausal symptom complex and may reflect GLP-1 receptor-mediated effects on hypothalamic thermoregulation and estrogen-sensitive neural circuits. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 19,508 condition-relevant adverse event reports for exenatide in the FDA AEMS database (from 32,744 total female-patient reports), menopause-relevant signals were present including vasomotor (night sweats n=2, hot flush n=1), mood (depression n=1, anxiety n=2, insomnia n=1, sleep disorder n=1), cognitive (memory impairment n=2, confusional state n=1), fatigue (n=3), and bone-related (osteoporosis n=1) signals. The general sample additionally showed nightmare (n=2) and sleep talking (n=2), adding CNS sleep architecture disruption evidence. This multi-domain signal cluster consistent with the menopausal transition is corroborated by the class-wide pattern. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 12,085 condition-relevant adverse event reports for liraglutide in the FDA AEMS database (from 29,717 total female-patient reports), vasomotor and menopausal symptom signals were identified including hot flush (n=1), night sweats (n=1), hyperhidrosis (n=4), alongside mood disturbances (depression n=4, anxiety n=3, insomnia n=3), cognitive concerns (memory impairment n=2, confusional state n=2), and urinary signals (urinary hesitation n=1). The vasomotor-mood-cognitive cluster recapitulates the menopausal symptom triad, and GLP-1R engagement in the hypothalamus may intersect with thermoregulatory and estrogen-sensitive circuits altered during the menopausal transition. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 20,277 condition-relevant adverse event reports for dulaglutide in the FDA AEMS database (from 44,406 total female-patient reports), menopausal-relevant signals included vasomotor symptoms (night sweats n=1, hyperhidrosis n=2), mood/cognitive disturbances (depression n=1, depressed mood n=1, anxiety n=3, memory impairment n=1, cognitive disorder n=1), fatigue (n=8), and asthenia (n=6). Though individual counts are low, the signal pattern is consistent with the class-wide menopause-relevant profile seen across all GLP-1 agonists in this analysis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 25,166 condition-relevant adverse event reports for tirzepatide in the FDA AEMS database (from 74,456 total female-patient reports), a menopause-relevant signal cluster emerged encompassing vasomotor symptoms (hyperhidrosis n=3, flushing n=2, cold sweat n=1), mood/cognitive disturbances (depression n=9, anxiety n=5, insomnia n=4, memory impairment n=4, brain fog n=2), and musculoskeletal/bone signals (osteoporosis n=1, bone density abnormal n=1, bone pain n=2). These multi-domain signals collectively mirror the menopausal symptom complex and are corroborated by the general sample showing weight and metabolic changes. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,176 condition-relevant adverse event reports for pramipexole in the FDA AEMS database (from 10,301 total female-patient reports), vasomotor symptoms (hyperhidrosis n=3, hot flush n=1, flushing n=1) co-occurred with a prominent mood cluster (depression n=7, anxiety n=8, insomnia n=6, cognitive disorder n=4) and fatigue/asthenia (n=15+8), representing a symptom constellation directly mapping onto menopausal complaints. General sample corroborated neuropsychiatric effects. Pramipexole's D3-preferring dopaminergic modulation of hypothalamic thermoregulatory and sleep circuits is relevant to menopausal vasomotor and neuropsychiatric symptom management. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 1,648 condition-relevant adverse event reports for rotigotine in the FDA AEMS database (from 6,009 total female-patient reports), mood/neurological signals (anxiety n=10, insomnia n=9, depression n=3, memory impairment n=4) co-occurred with vasomotor symptoms (flushing n=2, hyperhidrosis n=1) and were confirmed by the general sample's prominent confusional state (n=14). These patterns, along with osteoporosis (n=1), map onto menopausal symptomatology. Rotigotine's continuous transdermal D1/D2/D3 stimulation of hypothalamic thermoregulatory and sleep centers is relevant to the management of menopausal vasomotor and neuropsychiatric symptoms. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,313 condition-relevant adverse event reports for ropinirole in the FDA AEMS database (from 10,302 total female-patient reports), vasomotor signals (flushing n=5, hot flush n=3, hyperhidrosis n=2) were the strongest in the dopamine agonist class, alongside mood disturbance (anxiety n=8, insomnia n=7, depression n=3), fatigue/asthenia (n=9+10), memory impairment (n=3), and cognitive disorder (n=2). This vasomotor-mood-cognitive symptom triad directly maps onto the menopausal symptom complex, and ropinirole's D2/D3 hypothalamic thermoregulatory modulation is mechanistically relevant to vasomotor instability. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 999 condition-relevant adverse event reports for cabergoline in the FDA AEMS database (from 2,447 total female-patient reports), vasomotor symptoms including hot flush (n=4), hyperhidrosis (n=3), cold sweat (n=2), and flushing (n=1) appeared alongside mood disturbances (depression n=9, anxiety n=9, insomnia n=5) and osteoporosis (n=1), suggesting neuroendocrine disruption relevant to menopausal symptomatology. Cabergoline's potent prolactin suppression and dopaminergic modulation of thermoregulatory centers may interact with the estrogen-withdrawal-driven vasomotor instability characteristic of menopause. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 131 condition-relevant adverse event reports for bromocriptine in the FDA AEMS database (from 316 total female-patient reports), vasomotor and mood signals including hyperhidrosis (n=4), night sweats (n=1), depression (n=5), insomnia (n=6), and anxiety (n=4) alongside fatigue (n=10) and cognitive disturbance represent neuroendocrine effects relevant to menopausal symptomatology. Bromocriptine's dopaminergic modulation of the hypothalamic thermoregulatory center and prolactin axis directly intersects the estrogen-withdrawal-driven vasomotor and neuropsychiatric symptoms of menopause. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 22,530 condition-relevant adverse event reports for paroxetine in the FDA AEMS database (from 54,720 total female-patient reports), vasomotor and mood signals relevant to menopause were prominent including hyperhidrosis (n=5), night sweats (n=2), hot flush (n=2), flushing (n=1), depression (n=14), insomnia (n=10), anxiety (n=8), fatigue (n=25), and weight increased (n=8). Paroxetine (as Brisdelle 7.5mg) is the only FDA-approved non-hormonal treatment for menopausal vasomotor symptoms, and these AEMS signals are consistent with both the treated population and its established thermoregulatory mechanism. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 35,251 condition-relevant adverse event reports for fluoxetine in the FDA AEMS database (from 83,971 total female-patient reports), vasomotor and mood signals relevant to menopause were identified including hyperhidrosis (n=4), flushing (n=4), night sweats (n=1), hot flush (n=1), depression (n=17), insomnia (n=8), anxiety (n=14), and fatigue (n=13), alongside metabolic signals (weight increased n=8, weight decreased n=6). Fluoxetine has demonstrated efficacy in RCTs for vasomotor symptoms, and these AEMS signals are consistent with both the treated menopausal population and residual thermoregulatory dysfunction. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 34,200 condition-relevant adverse event reports for citalopram in the FDA AEMS database (from 83,257 total female-patient reports), vasomotor and mood signals relevant to menopause were identified including flushing (n=2), night sweats (n=2), hyperhidrosis (n=1), depression (n=18), insomnia (n=5), fatigue (n=14), anxiety (n=5), and asthenia (n=8), alongside osteoporosis (n=1), oophorectomy (n=1), and hysterectomy (n=1). The surgical menopause-related reports and vasomotor signals are consistent with clinical use of citalopram for menopausal mood and hot flush management. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 54,612 condition-relevant adverse event reports for sertraline in the FDA AEMS database (from 130,278 total female-patient reports), vasomotor and mood signals relevant to menopause were identified including hot flush (n=2), flushing (n=4), night sweats (n=1), hyperhidrosis (n=1), depression (n=16), insomnia (n=7), anxiety (n=12), and fatigue (n=12). These signals are consistent with sertraline's known role in modulating thermoregulatory serotonergic pathways in the hypothalamus, which are disrupted during estrogen withdrawal in menopause. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 17,165 condition-relevant adverse event reports for meloxicam in the FDA AEMS database (from 37,086 total female-patient reports), vasomotor signals (flushing n=3, hot flush n=2, hyperhidrosis n=2, night sweats n=1), mood/cognitive symptoms (depression n=5, anxiety n=7, insomnia n=5, memory impairment n=6, confusional state n=3), and urinary/bone signals (urinary incontinence n=1, cystitis n=2, osteoarthritis n=2) form a comprehensive menopause-relevant profile. The night sweats report specifically aligns with menopausal vasomotor symptoms. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,972 condition-relevant adverse event reports for celecoxib in the FDA AEMS database (from 83,065 total female-patient reports), vasomotor signals (hyperhidrosis n=2, flushing n=1, hot flush n=1, cold sweat n=1), mood/cognitive symptoms (depression n=2, memory impairment n=4, insomnia n=1, irritability n=1, mood altered n=1), and bone-relevant events (osteoporosis n=2, bone loss n=1, bone disorder n=2) form a menopause-relevant cluster. Celecoxib's COX-2 selectivity is particularly relevant to postmenopausal bone metabolism. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 68,147 condition-relevant adverse event reports for ibuprofen in the FDA AEMS database (from 159,407 total female-patient reports), vasomotor signals (hot flush n=3, flushing n=4, hyperhidrosis n=1), mood disturbance (depression n=9, anxiety n=11, insomnia n=2), and bone-related events (osteoporosis n=1, bone disorder n=1) form a cluster consistent with menopausal symptom profiles. The general sample also shows no enrichment for these, suggesting they arise in the gynae-relevant population. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 37,836 condition-relevant adverse event reports for diclofenac in the FDA AEMS database (from 86,286 total female-patient reports), vasomotor signals (hyperhidrosis n=9, flushing n=3, hot flush n=2), mood/cognitive symptoms (depression n=5, anxiety n=5, insomnia n=3, memory impairment n=3), urinary symptoms (urinary tract infection n=3, urinary incontinence n=1, urinary retention n=1), and bone signals (osteoporosis n=1, osteopenia n=2) form a comprehensive menopause-relevant cluster. The hyperhidrosis signal at 9% of sampled reports is notably elevated. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 38,880 condition-relevant adverse event reports for naproxen in the FDA AEMS database (from 85,294 total female-patient reports), vasomotor symptoms (flushing n=9, hot flush n=3, hyperhidrosis n=2), mood disturbance (depression n=5, insomnia n=4, anxiety n=4, memory impairment n=2), and bone/metabolic signals (osteoporosis n=2, weight increased n=10) form a comprehensive menopause-relevant profile. The flushing signal at 9% of sampled reports is notably elevated. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 24,875 condition-relevant adverse event reports for letrozole in the FDA AEMS database (from 54,797 total female-patient reports), prominent vasomotor symptoms (hot flush n=3, flushing n=2, hyperhidrosis n=1), mood disturbances (depression n=5, insomnia n=4, mood altered n=5, anxiety n=3, mood swings n=2, irritability n=4, sleep disorder n=3), and urogenital symptoms (vulvovaginal dryness n=1, urinary incontinence n=2) were observed, consistent with profound estrogen deprivation mimicking and intensifying menopausal symptoms. Letrozole's near-complete suppression of peripheral estrogen synthesis via CYP19A1 inhibition provides direct mechanistic insight into the estrogen-dependent symptom burden of menopause. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 15,012 condition-relevant adverse event reports for anastrozole in the FDA AEMS database (from 31,213 total female-patient reports), a striking vasomotor signal emerged with hot flush (n=13), night sweats (n=9), hyperhidrosis (n=7), and flushing (n=7), alongside prominent mood disruption (depression n=8, sleep disorder n=8, insomnia n=7, anxiety n=3) and urogenital atrophy markers (vulvovaginal dryness n=1, vaginal haemorrhage n=3, urinary incontinence n=2, bladder pain n=3). This is the most pronounced vasomotor signal among the three aromatase inhibitors, confirming profound estrogen deprivation that directly recapitulates and exacerbates the full menopausal symptom complex. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,735 condition-relevant adverse event reports for exemestane in the FDA AEMS database (from 18,954 total female-patient reports), vasomotor symptoms (hot flush n=5, hyperhidrosis n=2, flushing n=1), significant mood disturbances (depression n=3, insomnia n=6, anxiety n=4, irritability n=1, cognitive disorder n=1), and menopausal symptoms (n=2) confirm exemestane induces a menopausal-type estrogen deprivation syndrome. As an irreversible steroidal aromatase inactivator, exemestane's mechanism differs from reversible inhibitors (letrozole/anastrozole) yet produces the same vasomotor, mood, and urogenital symptom burden characteristic of estrogen-deficient menopause. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 89,421 condition-relevant adverse event reports for metformin in the FDA AEMS database (from 212,759 total female-patient reports), mood-related signals including depression, insomnia, anxiety, mood swings, and fatigue are documented alongside vasomotor symptoms (hot flush, flushing, hyperhidrosis). These signals intersect with menopause pathophysiology, and emerging evidence suggests metformin may modulate menopause-associated metabolic deterioration through AMPK activation and improved insulin sensitivity. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 28,321 condition-relevant adverse event reports for spironolactone in the FDA AEMS database (from 73,834 total female-patient reports), vasomotor and mood symptoms relevant to menopause were documented including hot flush (n=1), flushing (n=3), night sweats (n=1), hyperhidrosis (n=1), fatigue (n=19), insomnia (n=5), depression (n=2), anxiety (n=2), bone density decreased (n=1), and urinary symptoms. Spironolactone's anti-androgenic mechanism reduces residual androgen availability that becomes proportionally more important in the menopausal hormonal milieu, and its aldosterone antagonism affects fluid balance and thermoregulation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,493 condition-relevant adverse event reports for naltrexone in the FDA AEMS database (from 18,974 total female-patient reports), vasomotor symptoms including hot flush (n=4), hyperhidrosis (n=6), flushing (n=3), and night sweats (n=1) co-occurred with a substantial mood/neurological cluster (depression n=6, insomnia n=7, anxiety n=5, memory impairment n=4) and metabolic signals (weight decreased n=2, blood glucose changes). This vasomotor-mood-metabolic triad aligns with menopausal symptom domains, and naltrexone's modulation of central opioid tone intersects with thermoregulatory circuits in the hypothalamus known to be dysregulated in menopause. Full-scale analysis of all reports may reveal additional patterns.

Summary

A user reports that 5mg DHEA supplementation produced rapid and noticeable improvements in motivation, energy, exercise tolerance, soreness, and brain fog within 4 days, even after being on estrogen and progesterone HRT for over a year. While only one detailed first-person account meets strict criteria, the post generated significant community engagement suggesting wider interest and potential resonance.

Summary

A few women report that medical CBD oil improved sleep duration (from 3-4 hours to 6-7 hours), reduced anxiety, and lessened night sweat intensity during menopause. One user describes taking 12% CBD oil twice daily with notable improvements. This represents an off-label use for menopausal symptom management.

Summary

Multiple women report that Veozah (fezolinetant), a non-hormonal NK3 receptor antagonist, dramatically reduced or eliminated hot flashes and night sweats, particularly for women who cannot take hormonal treatments. One user reports elimination of hot flashes from the first dose after 14 years of suffering. However, cost remains a significant barrier, with some reporting $600/month without insurance coverage.

Summary

Multiple women report that magnesium glycinate supplementation helped with sleep quality, muscle tension, anxiety, and general well-being during perimenopause/menopause. Users typically report taking 400mg before bed. While magnesium is a known supplement, its specific use for menopausal sleep disturbance and anxiety represents a community-identified treatment pattern.

Summary

Multiple women report that quitting or significantly reducing alcohol consumption led to marked improvement in hot flashes, night sweats, sleep quality, anxiety, heart palpitations, and mood during perimenopause/menopause. Several describe it as one of the most impactful changes they made, noting that even one glass of wine now triggers symptom flare-ups.

Summary

Multiple women report that adding testosterone to their HRT regimen improved brain fog, energy, motivation, libido, fatigue, depression, joint pain, muscle retention, and bone density. One user reports that testosterone (combined with estrogen and progesterone) reversed severe osteoporosis. Several women describe dramatic improvements in cognitive function and quality of life. Despite this, many report significant barriers to obtaining prescriptions, with pharmacists and doctors questioning or refusing the treatment.

Summary

Multiple women report that correcting low iron/ferritin levels (even when technically within 'normal' range) dramatically improved energy, cognition, motivation, and mood during perimenopause. Users describe going from barely functioning to gardening, fishing with kids, and singing along to the radio. The connection between heavy perimenopausal bleeding and iron depletion is a recurring theme.

Summary

Multiple women report that creatine supplementation significantly improved brain fog, cognitive function, energy levels, and general well-being during perimenopause/menopause. Several users noted that higher doses (10-20g/day) were more effective than standard doses (3-5g/day). Some also reported improved sleep quality and muscle-building. Creatine is primarily known as a sports/bodybuilding supplement and its use for menopausal cognitive symptoms represents off-label/unexpected use.

Summary

Numerous women report that vaginal estradiol cream resolved or significantly improved urinary symptoms (urgency, frequency, recurrent UTIs, interstitial cystitis-like symptoms), vaginal dryness, painful sex, vaginal atrophy, and restored libido/sexual pleasure. Several women report being angry it wasn't prescribed sooner, as it resolved symptoms they had suffered with for years. Multiple users describe it as resolving bladder issues that had been misdiagnosed.

Summary

Multiple women report that collagen supplementation (typically hydrolyzed collagen powder at 5-15g/day) significantly reduced menopausal joint pain, with some reporting being able to sleep on their side again and regaining hand grip strength. One detailed account describes dose-dependent pain relief within 2 weeks of starting supplementation. This represents an off-label use of a supplement primarily marketed for skin health.

Summary

Multiple women report that correcting vitamin D deficiency significantly improved perimenopausal symptoms including night sweats, shortened cycles, PMS, energy, and cognition. One user (age 33) found that vitamin D supplementation resolved what she initially thought were perimenopause symptoms entirely. Others report it as a key part of their supplement stack for managing menopausal symptoms.